期刊文献+

达比加群酯的合成 被引量:6

Synthesis of Dabigatran Etexilate
原文传递
导出
摘要 4-甲胺基-3-硝基苯甲酸(2)经酰氯化后和3-(吡啶-2-基氨基)丙酸乙酯缩合,得3-[(4-甲胺基-3-硝基苯甲酰基)(吡啶-2-基)氨基]丙酸乙酯,再在Fe-Al-Cu复合催化剂作用下经水合肼还原、酰胺化后闭环、成脒及酰化反应等制得抗凝血药达比加群酯,总收率约33.6%(以2计)。 Dabigatran etexilate was synthesized from 4-methylamino-3-nitrobenzoic acid (2) by acylchlorination and condensation with ethyl 3- (pyridin-2-ylamino) propanoate to give ethyl 3- [ (4-methylamino-3-nitrobenzoyl) (pyridin- 2-yl) amino] propanoate, which was subjected to reduction by hydrazine in the presence of Fe-Al-Cu complex catalyst, amidation, cyclization, amidination and acylation with an overall yield of about 33.6 % (based on 2).
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2012年第12期961-964,共4页 Chinese Journal of Pharmaceuticals
基金 江苏省"六大人才高峰"高层次人才项目 连云港市工业攻关项目(CG1106)
关键词 达比加群酯 抗凝血药 Fe—Al-Cu复合催化剂 合成 dabigatran etexilate anticoagulant Fe-A1-Cu complex catalyst synthesis
  • 相关文献

参考文献10

二级参考文献50

  • 1郑淑玲,赵增国,张红艳.2-氯吡啶氮氧化物的合成方法研究[J].天津师范大学学报(自然科学版),2006,26(1):9-11. 被引量:5
  • 2Johnstone R A W,Wilby A H,Entwistle I D. Chem Rev[J] ,1985,85(2) :129. 被引量:1
  • 3Lauwiner M, Rys P, Wissmann J. Appl Catal A : Gen [ J ], 1998,172 ( 1 ) - 141. 被引量:1
  • 4Benz M,Kraan A M,Prins R. Appl Catal A:Gen[J] ,1998,172(1) :149. 被引量:1
  • 5Kumbhar P S, Sanchez-Valente J, Millet J M, Figueras F. J Catal[J].,2000,191 (2) :467. 被引量:1
  • 6Kumarraja M, Pitchumani K. Appl Catal A : Gen [ J ], 2004,265 ( 2 ) : 135. 被引量:1
  • 7WANG Li-Min(王利民),TIAN He(田禾).New Methods for Fine Organic Synthesis(精细有机合成新方法)[M].Beijing(北京):Chemical Industry Press(化学工业出版社),2004:26. 被引量:1
  • 8Ren P D,Pan S F,Dong T W,Wu S H. Synth Commun[J] ,1996,26(21 ) :3 903. 被引量:1
  • 9Lauauwiner M, Roth R, Rys P. Appl Catal A : Gen [ J ], 1999,177 ( 1 ) : 9. 被引量:1
  • 10[2]Max Lauwiner, Paul Rys, Jorg Wissmann. Reduction of aromatic nitro compounds with hydrazine hydrate in the presence of an iron oxide hydrozide catalyst[J]. Applied Catalyais, 1998, A: General 172:141 -148. 被引量:1

共引文献91

同被引文献48

  • 1Hauel N, Ries U, Priepke H, et al. Disubstituted bicycleheterocycles, their production and use as medicaments: WO,9837075 [P].1998-02-16. 被引量:1
  • 2Jirman J, Richter J, Lustig P. A method for the preparation ofdabigatran: WO, 2009111997 [P]. 2009-03-10. 被引量:1
  • 3Hauel NH, Nar H, Priepke H, et al. Structure-based designof novel potent nonpeptide thrombin inhibitors [J]. J MedChem,2002, 45 (9): 1757-1766. 被引量:1
  • 4林国强,马景毅,徐亮,等.一种合成非手性、非肽类的抗凝血酶抑制剂方法:中国,1861596 [P]. 2006-05-18. 被引量:1
  • 5Zerban G, Hausherr A, Schlarb K, et al. The method forproducing 4- (benzimidazolylmenthylamino) -benzamidines:WO, 2006000353 [P]. 2005-06-18. 被引量:1
  • 6Zerban G,Hausherr A, Hamm R, et al. Improved process forpreparation of the salts of 4- (benzimidazolylmenthylamino) .benzamidines: WO, 2007071743 [P]. 2006-12-20. 被引量:1
  • 7Heddesheimer I, Scholz U. Process for the manufacture of anintermediate in the synthesis of dabigatran: WO, 2009153214[P]. 2009-06-12. 被引量:1
  • 8HUGHES B. First oral warfarin alternative approved in the US[J]. Nat. Rev. Drug. Discov. ,2010,9(12) :903- 906. 被引量:1
  • 9B1ECH S, EBNER T, LUDWING-SCHWELLINGER E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in hunman [ J ]. Drug. Metab. Dispos. , 2008,36 ( 2 ) : 386 -399. 被引量:1
  • 10HAUEL N H,RIES U,PRIEPKE H,et al. Preparation of amidinophenylethyl benzimidazolyl carboxamides and re- lated compounds as thrombin inhibitors:WO, 9 837 075 [ P]. 1998-08-27. 被引量:1

引证文献6

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部